Patanjali’s team of scientists have developed a herbal approach aimed at addressing the root cause of psoriasis. In preclinical studies, the team tested Psorogrit tablets and Divya Taila using ...

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological ...

"With this new tablet formulation, we are making treatment simpler and more convenient—an important step forward for patients facing certain B-cell cancers." The recommended dose of BRUKINSA ...

The US Food and Drug Administration (FDA) has granted approval to a tablet formulation of BeOne Medicines’ targeted cancer drug Brukinsa (zanubrutinib). The company formerly known as BeiGene announced ...

--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ...

The European Commission approved a tablet formulation of SMA treatment Evrysdi, a form aimed at giving patients more flexibility.

"With this new tablet formulation, we are making treatment simpler and more convenient-an important step forward for patients facing certain B-cell cancers." The recommended dose of BRUKINSA ...

LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced ...